GLP-1 side effects: how common they are, when they ease and when to get help

The GLP-1 side effects people run into most often are stomach problems. Nausea, diarrhea, vomiting, constipation and stomach pain appear on the list of most common reactions for all four medications covered here: Zepbound, Wegovy, Mounjaro and Ozempic.1,2,3,4

Below: how often each one was reported in the label trials, when symptoms tend to show up, what helps and which warning signs should not wait. Zepbound and Wegovy are FDA-approved for weight management. Mounjaro and Ozempic are approved for type 2 diabetes, not weight loss, so their figures come from diabetes trials.

Written by the FitRx care team. Last updated November 18, 2026. Sources are listed in the references.

Key takeaways

  • Stomach symptoms are the most common side effects on all four labels, and nausea is first on every list.1,2,3,4
  • In the label trials, nausea was reported by 12% to 44% of people on medication and by 4% to 16% of people on placebo.
  • Side effects cluster around dose increases, so each injection starts low and steps up no faster than every 4 weeks.
  • Severe stomach pain that will not go away, yellowing skin or eyes, a lump in the neck, or swelling of the face or throat need attention right away.

See if you qualify

Which GLP-1 side effects are most common?

Five side effects are on the “most common” list of all four labels: nausea, diarrhea, vomiting, constipation and abdominal (stomach) pain.1,2,3,4 Clinicians call them gastrointestinal, or GI, reactions.

There is a plain reason they gather there. Each label says the medication delays gastric emptying: food leaves your stomach more slowly, so a meal that once felt ordinary can feel like too much.

The lists for the two weight management products run longer. Zepbound’s adds indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss and acid reflux. Wegovy’s adds, among others, headache, fatigue, dizziness, bloating, hair loss and dysesthesia, an altered skin sensation. Mounjaro’s adds decreased appetite and indigestion. Ozempic’s stops at the five.

New to the vocabulary? Our guide to what GLP-1 means explains how this drug class works.

How common is nausea?

Nausea is first on every list. In the label trials it was reported by 12% (Mounjaro 5 mg) to 44% (Wegovy 2.4 mg) of people taking the medication, and by 4% to 16% of people taking placebo. Keep that second range in mind: some stomach upset happens with or without the drug, so not every queasy day on a GLP-1 is caused by the GLP-1.

Side effects beyond the stomach

The weight management labels also report these, shown against placebo from the same trials:1,2

  • Fatigue. 5% to 7% on Zepbound versus 3%; 11% on Wegovy versus 5%.
  • Headache. 14% on Wegovy versus 10%.
  • Dizziness. 4% to 5% on Zepbound versus 2%; 8% on Wegovy versus 4%.
  • Injection site reactions. 6% to 8% on Zepbound versus 2%.
  • Hair loss. 4% to 5% on Zepbound and 3% on Wegovy, versus 1%.

When do GLP-1 side effects start, and how long do they last?

It depends on your dose schedule more than on the calendar. The trial data tie stomach side effects to the weeks when the dose is going up:

  • The Ozempic label says most nausea, vomiting and diarrhea happened during dose escalation.4
  • In SURMOUNT-5, a 72-week trial comparing tirzepatide with semaglutide in 751 adults with obesity, most adverse events were gastrointestinal, mild to moderate, and occurred mainly during dose escalation.5
  • A separate published analysis looked at how well people tolerated semaglutide 2.4 mg and how stomach side effects related to weight loss.6

So the practical question is how long the step-up phase runs.1,2,3,4

MedicationStarting doseStep-ups on the label
Zepbound, Mounjaro2.5 mg weekly2.5 mg steps, at least 4 weeks apart, up to 15 mg
Wegovy pen0.25 mg weeklyEvery 4 weeks through week 16; maintenance from week 17
Wegovy pill1.5 mg dailyEvery 30 days; 25 mg from day 91
Ozempic0.25 mg weekly0.5 mg after 4 weeks; later steps at least 4 weeks apart, up to 2 mg

Schedules from each prescribing information. Your provider sets your actual schedule, and not everyone needs the top dose.

At the fastest pace the labels allow, Zepbound 15 mg is at least 20 weeks away and Wegovy’s maintenance dose starts in week 17. Those first months are when new stomach symptoms are most likely. We cannot give you a number of days for any one episode: it varies by person and by step.

If they do not settle

Tell your provider. “At least 4 weeks” on a dose is a minimum, not a deadline, and the Wegovy label says a prescriber can consider delaying the next increase by 4 weeks when a step is not tolerated.2

Few people in the diabetes trials quit over stomach symptoms. In Ozempic’s trials, 3.1% (0.5 mg) and 3.8% (1 mg) stopped treatment because of them, versus 0.4% on placebo. For Mounjaro the figures were 3.0%, 5.4% and 6.6% across its three doses.3,4

Which GLP-1 side effects are serious, and what are the warning signs?

All four labels also warn about problems that need quick attention, and their medication guides describe the warning signs in plain terms. Learn them before your first dose.1,2,3,4

What the labels warn aboutWarning signs
Pancreatitis (an inflamed pancreas)Severe pain in your stomach area that will not go away, with or without vomiting, sometimes felt in your back
Gallbladder problems, including gallstonesPain in your upper stomach, fever, yellowing of your skin or eyes, clay-colored stools
Kidney injury from fluid lossVomiting or diarrhea that keeps you from holding down fluids
Serious allergic reactionsSwelling of your face, lips, tongue or throat; trouble breathing
Severe stomach reactionsStomach symptoms that are severe or do not let up. Not recommended with severe gastroparesis
Low blood sugarMainly when combined with insulin or a sulfonylurea
Diabetic eye disease complicationsVision changes, if you have type 2 diabetes

Any of these warning signs is a reason to contact a clinician right away, not at your next check-in. For swelling of the face or throat or trouble breathing, call 911.

Boxed warning: thyroid C-cell tumors. Tirzepatide and semaglutide caused these tumors in rodents; whether they do in people is not known. Do not use these medications if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.1,2,3,4

If you have surgery or a procedure coming up

The labels warn that stomach contents can get into the lungs during general anesthesia or deep sedation. Tell your surgical team you take a GLP-1 when the procedure is scheduled.

The Wegovy label adds one more warning: an increase in heart rate, which prescribers are told to monitor.2 You can also report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How do side effect rates differ between Zepbound, Wegovy, Mounjaro and Ozempic?

This table lines up the label figures for the main stomach side effects. Each cell shows the share of people reporting the reaction at each dose, with the placebo rate from the same trials in parentheses.1,2,3,4

Side effectZepbound 5, 10, 15 mgWegovy 2.4 mgMounjaro 5, 10, 15 mgOzempic 0.5, 1 mg
Nausea25%, 29%, 28% (8%)44% (16%)12%, 15%, 18% (4%)15.8%, 20.3% (6.1%)
Diarrhea19%, 21%, 23% (8%)30% (16%)12%, 13%, 17% (9%)8.5%, 8.8% (1.9%)
Vomiting8%, 11%, 13% (2%)24% (6%)5%, 5%, 9% (2%)5.0%, 9.2% (2.3%)
Constipation17%, 14%, 11% (5%)24% (11%)6%, 6%, 7% (1%)5.0%, 3.1% (1.5%)
Abdominal pain9%, 9%, 10% (5%)20% (10%)6%, 5%, 5% (4%)7.3%, 5.7% (4.6%)

From each prescribing information. Zepbound and Wegovy figures come from weight management trials; Mounjaro and Ozempic figures come from type 2 diabetes trials. Mounjaro and Ozempic are not FDA-approved for weight loss.

These rows are not head-to-head. Each column comes from different trials, with different people, conditions and lengths. Even placebo nausea ranged from 4% in the Mounjaro trials to 16% in the Wegovy trials. Use the table to see what each label reports, not to rank the drugs.

Patterns inside a column are firmer ground. Nausea rose with dose on Mounjaro (12% to 18%) and Ozempic (15.8% to 20.3%). Not everything climbs: constipation on Zepbound was 17% at 5 mg and 11% at 15 mg.

The two tirzepatide products

Zepbound and Mounjaro contain the same molecule, tirzepatide. In Mounjaro’s trials, 37.1% to 43.6% of people reported some stomach or gut reaction, compared with 20.4% on placebo.3 Both labels carry an instruction that is easy to miss: if you take birth control pills, switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.1,3

The two semaglutide products

Wegovy and Ozempic both contain semaglutide. In Ozempic’s trials, 32.7% of people on 0.5 mg and 36.4% on 1 mg reported a stomach or gut reaction, compared with 15.3% on placebo. In a separate trial of the 2 mg dose, the figures were 34% on 2 mg and 30.8% on 1 mg.4 See the Ozempic dosage guide for each step, or Mounjaro vs. Ozempic for a fuller comparison.

Wegovy also has a 7.2 mg dose (Wegovy HD), allowed only after 2.4 mg has been tolerated for at least 4 weeks and when more weight reduction is clinically indicated. Its trial reported:2

Side effectPlaceboWegovy 2.4 mgWegovy 7.2 mg
Nausea13%35%39%
Vomiting6%16%22%
Altered skin sensation (dysesthesia)0%6%22%
Constipation8%19%20%
Hair loss1%3%6%

The standout is dysesthesia: 22% of people on 7.2 mg reported it, against 6% on 2.4 mg and none on placebo.

What about compounded medication?

None of these percentages describe compounded medication. Compounded semaglutide and compounded tirzepatide are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. They are not generics of the brand-name drugs and were not tested in the brand-name trials.7 A licensed provider decides whether one is appropriate.

Vials and syringes add their own risk. The FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide: patients measuring the wrong dose and clinicians miscalculating doses.8 If you draw up your own doses, check each one against your pharmacy’s written instructions and ask before injecting if anything is unclear. The tirzepatide units guide shows how milligrams and syringe units relate.

What helps with GLP-1 side effects?

The best-supported tools are the ones in the labels and medication guides: go up slowly, drink fluids and keep your provider informed.

  1. Let the schedule do its job

    Starting low is the side effect strategy built into these drugs. Every dose step waits at least 4 weeks, and going faster than the label allows is not a shortcut.1,2

  2. Ask about staying on your dose

    If a new dose hits hard, your provider can hold you there longer before the next increase. Make that call together, not by adjusting doses yourself.

  3. Drink fluids

    The medication guides for all four products say to drink fluids to lower the chance of dehydration when you have nausea, vomiting or diarrhea. Fluid loss is behind the kidney injury warning.

  4. Eat for a slower stomach

    Modest portions, an unhurried pace and putting the fork down once you feel full are sensible habits. These are general tips, not label instructions.

  5. Rotate where you inject

    The Zepbound label says to rotate injection sites: the abdomen or thigh, or the back of the upper arm if someone else gives the injection.1

  6. Tell your provider early

    Mention side effects when they start, along with every medicine you take by mouth, since slower stomach emptying may affect how oral medicines are absorbed. FitRx members have unlimited secure messaging with their provider and monthly video or phone visits.

  7. Know when not to wait

    Severe stomach pain that will not go away, yellowing skin or eyes, or being unable to keep fluids down means contacting a clinician right away. Trouble breathing or swelling of the face or throat means calling 911.

We have left out over-the-counter nausea remedies, laxatives and supplements on purpose. Ask your provider or pharmacist before adding one.

Talk with a licensed provider

What do we know about long-term GLP-1 side effects?

These are long-term medications, so the long view matters. Here is what the labels and published research support.

Muscle along with fat

Weight lost on GLP-1 based therapy includes some lean mass, not only fat, and researchers have reviewed ways to limit it.9 The protein calculator gives a daily range to discuss with your care team.

Gallstones and hair loss

All four labels warn about acute gallbladder disease. Wegovy’s reports gallstones in 1.6% of people on the injection versus 0.7% on placebo, and 2.5% on the tablets versus 1%.2 Hair loss reached 6% in the Wegovy 7.2 mg trial.

Open questions

A 2023 analysis in JAMA examined signals for pancreatitis, gastroparesis and bowel obstruction among people taking GLP-1 medications for weight loss.10 The thyroid question is also open: the tumors behind the boxed warning were seen in rodents, and the human risk is unknown.

What happens after stopping

Stopping is its own long-term question, because weight tends to return. In the STEP 1 extension, people who had lost an average of 17.3% on semaglutide regained 11.6 percentage points in the year after stopping, a net loss of 5.6% at week 120.11 In SURMOUNT-4, after an average 20.9% loss over 36 weeks on tirzepatide, people who continued lost a further 5.5% by week 88, while those switched to placebo regained 14.0%.12 These are averages. Talk with your provider before stopping.

Who should avoid GLP-1 medications?

According to the labels, do not use these medications if:1,2,3,4

  • You or a family member has had medullary thyroid carcinoma (MTC).
  • You have MEN 2.
  • You have had a serious allergic reaction to tirzepatide or semaglutide.

Other situations call for a different plan:

  • Severe gastroparesis. Not recommended on any of the four labels.
  • Pregnancy. The tirzepatide and Wegovy labels warn of possible fetal harm. Zepbound should be stopped when pregnancy is recognized, and the semaglutide labels say to stop at least 2 months before a planned pregnancy.1,2,3,4
  • Breastfeeding. Not recommended during treatment with Wegovy tablets. Ask your provider about any other GLP-1.2
  • A similar drug already. Zepbound is not recommended with other tirzepatide products or any GLP-1 receptor agonist.

For weight management, the Zepbound and Wegovy labels cover adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Check yours with the BMI calculator. FitRx treats adults 18 and older, a licensed provider reviews every intake, and not everyone qualifies.

GLP-1 side effects: common questions

Which side effect do people on a GLP-1 report most?

Nausea, which heads the list of most common reactions on all four labels. Reported rates ran from 12% to 18% on Mounjaro and 15.8% to 20.3% on Ozempic in diabetes trials, and from 25% to 29% on Zepbound up to 44% on Wegovy 2.4 mg in weight management trials. Placebo groups reported it too, at 4% to 16%.

Will GLP-1 side effects ease with time?

Often they ease once the dose stops changing, because the trial data tie stomach side effects mainly to dose escalation. There is no fixed number of days, and it is not a promise for every person. If symptoms hang on, tell your provider. Staying on a dose longer than the 4-week minimum is an option.

Is one GLP-1 easier on the stomach than the others?

The label numbers cannot settle that, because each drug was tested in different trials with different people. Placebo nausea alone ranged from 4% to 16%. In SURMOUNT-5, which compared tirzepatide and semaglutide directly, most adverse events were gastrointestinal, mild to moderate, and mainly during dose escalation.

Is hair loss a side effect of GLP-1 medications?

Both weight management labels list it. In Zepbound's trials 4% to 5% of people reported hair loss, and in Wegovy's 2.4 mg trials 3% did, while placebo groups sat at 1%. The Wegovy 7.2 mg trial recorded 6%. Tell your provider if you notice it.

Is feeling tired a GLP-1 side effect?

It can be. Both weight management labels list fatigue: 5% to 7% of people in Zepbound's trials reported it against 3% on placebo, and 11% in Wegovy's 2.4 mg trials against 5%. Mention tiredness that lingers to your provider.

Are there long-term risks with GLP-1 medications?

Three come up most. Gallstones: the Wegovy label reports them in 1.6% of people on the injection and 0.7% on placebo. Body composition: some of the weight lost is lean mass. And the thyroid question: every label has a boxed warning based on tumors found in rodents, with no answer yet on human risk.

Do Mounjaro and Ozempic have the same side effects as Zepbound and Wegovy?

The types are the same, because Mounjaro shares its ingredient with Zepbound and Ozempic shares its ingredient with Wegovy. The reported rates differ because the doses and the trials differ. Mounjaro and Ozempic are FDA-approved for type 2 diabetes, not for weight loss, and their label figures come from diabetes trials.

Does compounded semaglutide or tirzepatide have different side effects?

The label percentages come from brand-name trials, and compounded medication was not tested in them. Compounded semaglutide and compounded tirzepatide are not FDA-approved, the FDA does not review them for safety, effectiveness or quality, and they are not generics of the brand-name drugs. The FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. A licensed provider decides whether a compounded medication is appropriate.

Which GLP-1 side effects mean I should get help right away?

The medication guides flag these: severe stomach pain that does not let up, with or without vomiting; upper stomach pain with fever, yellow skin or eyes, or clay-colored stools; and a lump or swelling in the neck, hoarseness or trouble swallowing. Contact a clinician promptly for any of them. Trouble breathing or a swelling face or throat is a 911 call.

References (12)
  1. Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  2. Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
  3. Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
  4. Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
  6. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. https://pubmed.ncbi.nlm.nih.gov/34514682/
  7. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  8. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  9. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/
  10. Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795-1797. https://pubmed.ncbi.nlm.nih.gov/37796527/
  11. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
  12. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.

Have questions about side effects before you start?

A licensed FitRx provider reviews your health history and current medications and decides whether a GLP-1 medication is appropriate for you. You can message them with questions as you go.

See if you qualify

FitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.

A person messaging their FitRx care team in the patient portal on a phone

The FitRx care team

You should not have to guess whether a symptom is normal

A table of percentages tells you what happened in a trial, not what to do about your own rough week. FitRx members work with a licensed provider, a care coordinator and a coach, all online, so side effect questions reach people who know your history. Emergencies still need emergency care.

  • U.S.-licensed providers review every intake and make every prescribing decision
  • Unlimited secure messaging, plus monthly video or phone visits
  • A care coordinator and a coach alongside your provider
  • An insurance coordination team for brand-name GLP-1 prior authorizations

This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.

GLP-1 medications our providers can prescribe

A provider decides which medication, if any, fits your health history. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as the brand-name products.